Publications by authors named "Takao Takizawa"
A 72-year-old woman who had been treated for coxotuberculosis was examined because of persistent hemoptysis. Chest X-ray films and CT scans revealed atelectasis of the right middle lobe and bronchial calcification. Bronchoscopy showed a yellow broncholith with pus 1 cm from the orifice of the right B4 bronchus.
View Article and Find Full Text PDFArticle Synopsis
- The text discusses a case of a 69-year-old woman who developed esophageal candidiasis after using inhaled steroids daily for her chronic allergic rhinitis.
- After experiencing difficulty swallowing, an endoscopy revealed both pharyngitis and esophageal candidiasis, leading to a cessation of the steroid and treatment with Azunol mouthwash.
- Follow-up examinations showed significant improvement in her condition and no further symptoms, suggesting that the esophageal candidiasis was linked to the inhalation steroid use.
Article Synopsis
- A survey of doctors in Saitama prefecture found that theophylline (77%), inhaled corticosteroids (75%), and leukotriene modifiers (64%) are the most commonly prescribed medications for mild persistent asthma.
- Theophylline was prioritized over inhaled beta2-agonists during asthma exacerbations, suggesting an over-reliance on this medication.
- Doctors specializing in respiratory or allergic medicine preferred using inhaled corticosteroids, often starting with higher doses and continuing treatment even after asthma control was achieved.
Article Synopsis
- Gastrointestinal endoscopy revealed high-grade esophageal candidiasis in two bronchial asthma patients using inhaled corticosteroids, specifically fluticasone propionate (FP).
- Out of 20 long-term FP users, 35% showed signs of esophageal candidiasis, a rate higher than usual, suggesting that inhaled corticosteroids may linger in the esophagus and contribute to this condition.
- Adjusting the timing of FP inhalation improved one patient's candidiasis grade, indicating that avoiding immediate sleep after inhalation can help reduce esophageal irritation.
Nateglinide is a new, fast-onset, short-acting hypoglycemic agent, which increases early phase insulin secretion and the total amount of insulin secreted. However, it is not clear which of these effects contribute more to the decrease in postprandial plasma glucose (PG). To further clarify the pharmacologic actions of nateglinide, we investigated the changes in PG and insulin levels during meal tolerance tests with and without nateglinide.
View Article and Find Full Text PDF